Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Spondyloarthritis encompasses a group of common inflammatory diseases caused by an overactive immune response affecting up to half a million people in the UK alone.

Model for role of GM-CSF in spondyloarthritis chronic inflammation. GM-CSF is produced by joint-resident innate lymphoid cell (ILC) and infiltrating CD4 T cells and acts to activate monocytes to produce other molecules that propagate the inflammatory response.
Model for role of GM-CSF in spondyloarthritis chronic inflammation. GM-CSF is produced by joint-resident innate lymphoid cell (ILC) and infiltrating CD4 T cells and acts to activate monocytes to produce other molecules that propagate the inflammatory response.

In collaboration with the Wellcome Trust Centre for Human Genetic, NDORMS researchers have been working to establish the type of disease-causing immune cells in this condition in order to identify new treatments. Spondyloarthritis encompasses a group of common inflammatory diseases thought to be driven by IL-17A-secreting type-17 lymphocytes.

In a recent article published in Nature Communications the researchers identified the expansion of a subset of immune cells in patient blood and joint fluid that are likely to be driving the inflammation by releasing a particular inflammatory molecule called GM-CSF.  Both GM-CSF+ and IL-17A  cells express increased levels of GPR65, a proton-sensing receptor associated with spondyloarthritis. Silencing GPR65 in primary CD4 T cells reduces GM-CSF production. GM-CSF and GPR65 may thus serve as targets for therapeutic intervention of spondyloarthritis.

Commenting on the findings, lead researcher Dr Hussein Al-Mossawi says: “It is hoped that this research will inform new trials that target GM-CSF in order to treat patients who suffer from this disease.”

Read the full article on Nature Communications:

 The research is funded by the Wellcome Trust and the National Institute for Health Research (NIHR).

Funding Bodies

NIHR NHS_Logo_Funded by Stamp.jpg

wellcome_trust_logo.png

Similar stories

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Study reveals the safety of bisphosphonates in chronic kidney disease

Main

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.